Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid
The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previousl...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Dall, P. [verfasserIn] Meerpohl, H.G. [verfasserIn] Henne, K. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA: Blackwell Science Inc. ; 1996 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2002 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: International journal of gynecological cancer - Oxford [u.a.] : Wiley-Blackwell, 1991, 6(1996), 1, Seite 0 |
| Übergeordnetes Werk: |
volume:6 ; year:1996 ; number:1 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1046/j.1525-1438.1996.06010020.x |
|---|
| Katalog-ID: |
NLEJ239409078 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ239409078 | ||
| 003 | DE-627 | ||
| 005 | 20210707084700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120426s1996 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1046/j.1525-1438.1996.06010020.x |2 doi | |
| 035 | |a (DE-627)NLEJ239409078 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Dall, P. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid |
| 264 | 1 | |a Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA |b Blackwell Science Inc. |c 1996 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted. | ||
| 533 | |d 2002 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2002|||||||||| | ||
| 650 | 4 | |a 5-fluorouracil | |
| 700 | 1 | |a Meerpohl, H.G. |e verfasserin |4 aut | |
| 700 | 1 | |a Henne, K. |e verfasserin |4 aut | |
| 700 | 1 | |a Du Bois, A. |4 oth | |
| 700 | 1 | |a Achterrath, W. |4 oth | |
| 700 | 1 | |a Frommhold, H. |4 oth | |
| 700 | 1 | |a Pfleiderer, A. |4 oth | |
| 773 | 0 | 8 | |i In |t International journal of gynecological cancer |d Oxford [u.a.] : Wiley-Blackwell, 1991 |g 6(1996), 1, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926197 |w (DE-600)2009072-9 |x 1525-1438 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:1996 |g number:1 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1046/j.1525-1438.1996.06010020.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 1996 |e 1 |h 0 | ||
| author_variant |
p d pd h m hm k h kh |
|---|---|
| matchkey_str |
article:15251438:1996----::obndaiceohrpiavnecriacneahsitilihekyplecrol |
| hierarchy_sort_str |
1996 |
| publishDate |
1996 |
| allfields |
10.1046/j.1525-1438.1996.06010020.x doi (DE-627)NLEJ239409078 DE-627 ger DE-627 rakwb Dall, P. verfasserin aut Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA Blackwell Science Inc. 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| 5-fluorouracil Meerpohl, H.G. verfasserin aut Henne, K. verfasserin aut Du Bois, A. oth Achterrath, W. oth Frommhold, H. oth Pfleiderer, A. oth In International journal of gynecological cancer Oxford [u.a.] : Wiley-Blackwell, 1991 6(1996), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926197 (DE-600)2009072-9 1525-1438 nnns volume:6 year:1996 number:1 pages:0 http://dx.doi.org/10.1046/j.1525-1438.1996.06010020.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 6 1996 1 0 |
| spelling |
10.1046/j.1525-1438.1996.06010020.x doi (DE-627)NLEJ239409078 DE-627 ger DE-627 rakwb Dall, P. verfasserin aut Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA Blackwell Science Inc. 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| 5-fluorouracil Meerpohl, H.G. verfasserin aut Henne, K. verfasserin aut Du Bois, A. oth Achterrath, W. oth Frommhold, H. oth Pfleiderer, A. oth In International journal of gynecological cancer Oxford [u.a.] : Wiley-Blackwell, 1991 6(1996), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926197 (DE-600)2009072-9 1525-1438 nnns volume:6 year:1996 number:1 pages:0 http://dx.doi.org/10.1046/j.1525-1438.1996.06010020.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 6 1996 1 0 |
| allfields_unstemmed |
10.1046/j.1525-1438.1996.06010020.x doi (DE-627)NLEJ239409078 DE-627 ger DE-627 rakwb Dall, P. verfasserin aut Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA Blackwell Science Inc. 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| 5-fluorouracil Meerpohl, H.G. verfasserin aut Henne, K. verfasserin aut Du Bois, A. oth Achterrath, W. oth Frommhold, H. oth Pfleiderer, A. oth In International journal of gynecological cancer Oxford [u.a.] : Wiley-Blackwell, 1991 6(1996), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926197 (DE-600)2009072-9 1525-1438 nnns volume:6 year:1996 number:1 pages:0 http://dx.doi.org/10.1046/j.1525-1438.1996.06010020.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 6 1996 1 0 |
| allfieldsGer |
10.1046/j.1525-1438.1996.06010020.x doi (DE-627)NLEJ239409078 DE-627 ger DE-627 rakwb Dall, P. verfasserin aut Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA Blackwell Science Inc. 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| 5-fluorouracil Meerpohl, H.G. verfasserin aut Henne, K. verfasserin aut Du Bois, A. oth Achterrath, W. oth Frommhold, H. oth Pfleiderer, A. oth In International journal of gynecological cancer Oxford [u.a.] : Wiley-Blackwell, 1991 6(1996), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926197 (DE-600)2009072-9 1525-1438 nnns volume:6 year:1996 number:1 pages:0 http://dx.doi.org/10.1046/j.1525-1438.1996.06010020.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 6 1996 1 0 |
| allfieldsSound |
10.1046/j.1525-1438.1996.06010020.x doi (DE-627)NLEJ239409078 DE-627 ger DE-627 rakwb Dall, P. verfasserin aut Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA Blackwell Science Inc. 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| 5-fluorouracil Meerpohl, H.G. verfasserin aut Henne, K. verfasserin aut Du Bois, A. oth Achterrath, W. oth Frommhold, H. oth Pfleiderer, A. oth In International journal of gynecological cancer Oxford [u.a.] : Wiley-Blackwell, 1991 6(1996), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926197 (DE-600)2009072-9 1525-1438 nnns volume:6 year:1996 number:1 pages:0 http://dx.doi.org/10.1046/j.1525-1438.1996.06010020.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 6 1996 1 0 |
| source |
In International journal of gynecological cancer 6(1996), 1, Seite 0 volume:6 year:1996 number:1 pages:0 |
| sourceStr |
In International journal of gynecological cancer 6(1996), 1, Seite 0 volume:6 year:1996 number:1 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
5-fluorouracil |
| isfreeaccess_bool |
false |
| container_title |
International journal of gynecological cancer |
| authorswithroles_txt_mv |
Dall, P. @@aut@@ Meerpohl, H.G. @@aut@@ Henne, K. @@aut@@ Du Bois, A. @@oth@@ Achterrath, W. @@oth@@ Frommhold, H. @@oth@@ Pfleiderer, A. @@oth@@ |
| publishDateDaySort_date |
1996-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926197 |
| id |
NLEJ239409078 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ239409078</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707084700.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120426s1996 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1525-1438.1996.06010020.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ239409078</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dall, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA</subfield><subfield code="b">Blackwell Science Inc.</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">5-fluorouracil</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meerpohl, H.G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Henne, K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Du Bois, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Achterrath, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Frommhold, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pfleiderer, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International journal of gynecological cancer</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1991</subfield><subfield code="g">6(1996), 1, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926197</subfield><subfield code="w">(DE-600)2009072-9</subfield><subfield code="x">1525-1438</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:1996</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1525-1438.1996.06010020.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">1996</subfield><subfield code="e">1</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Dall, P. |
| spellingShingle |
Dall, P. misc 5-fluorouracil Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid |
| authorStr |
Dall, P. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926197 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1525-1438 |
| topic_title |
Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid 5-fluorouracil |
| publisher |
Blackwell Science Inc. |
| publisherStr |
Blackwell Science Inc. |
| topic |
misc 5-fluorouracil |
| topic_unstemmed |
misc 5-fluorouracil |
| topic_browse |
misc 5-fluorouracil |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
b a d ba bad w a wa h f hf a p ap |
| hierarchy_parent_title |
International journal of gynecological cancer |
| hierarchy_parent_id |
NLEJ243926197 |
| hierarchy_top_title |
International journal of gynecological cancer |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926197 (DE-600)2009072-9 |
| title |
Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid |
| ctrlnum |
(DE-627)NLEJ239409078 |
| title_full |
Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid |
| author_sort |
Dall, P. |
| journal |
International journal of gynecological cancer |
| journalStr |
International journal of gynecological cancer |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1996 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Dall, P. Meerpohl, H.G. Henne, K. |
| container_volume |
6 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Dall, P. |
| doi_str_mv |
10.1046/j.1525-1438.1996.06010020.x |
| author2-role |
verfasserin |
| title_sort |
combined radio-chemotherapy in advanced cervical cancer: a phase-ii trial with weekly applied carboplatin, 5-fluorouracil and folinic acid |
| title_auth |
Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid |
| abstract |
The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted. |
| abstractGer |
The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted. |
| abstract_unstemmed |
The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
1 |
| title_short |
Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid |
| url |
http://dx.doi.org/10.1046/j.1525-1438.1996.06010020.x |
| remote_bool |
true |
| author2 |
Meerpohl, H.G. Henne, K. Du Bois, A. Achterrath, W. Frommhold, H. Pfleiderer, A. |
| author2Str |
Meerpohl, H.G. Henne, K. Du Bois, A. Achterrath, W. Frommhold, H. Pfleiderer, A. |
| ppnlink |
NLEJ243926197 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1046/j.1525-1438.1996.06010020.x |
| up_date |
2024-07-06T07:24:32.876Z |
| _version_ |
1803813569562673152 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ239409078</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707084700.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120426s1996 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1525-1438.1996.06010020.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ239409078</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dall, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA</subfield><subfield code="b">Blackwell Science Inc.</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The 5-year survival of patients with advanced cervical cancer is poor. Major problems are the high frequency of pelvic recurrences and distant metastases. To prevent both, various efforts have been made to combine local radiotherapy with systemic chemotherapy. In this prospective study, 28 previously untreated patients with advanced cervical cancer (FIGO IIB-IVB) were treated with a newly designed therapy consisting of fractionated external beam irradiation (54 Gy) followed by two intracavitary cesium (Cs) applications (2 × 15 Gy), combined with carboplatin (70 mg m−2), 5-fluorouracil (5-FU) (400 mg m−2) and folinic acid (400 mg m−2). Cytotoxic agents were given intravenously on days 1, 8, 15, 22 and 29 as 1-day courses during external irradiation followed by three 3-day courses with carboplatin (100 mg m−2 i.v. daily), 5-FU (400 mg m−2 i.v. daily) and folinic acid (400 mg m−2 i.v. daily) after 8, 12 and 16 weeks of treatment.Acute toxicities ( <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1048891X:IJG06010020:ges" location="ges.gif"/> WHO grade 2) were leucopenia (27 of 28 patients), diarrhea (23/28), abdominal pain (19/28), nausea (14/28) and skin desquamation (12/28). Clinically diagnosed pelvic response was achieved in 88.5% (23/26) with a complete response of 34.5% (9/26). As yet, 19 of 26 patients (73.1%) are alive and well (persistent complete/partial remission), two patients (7.7%) are alive with local progression, four (15.4%) have died from pelvic and/or distal recurrence and one (3.8%) died some weeks after the start of therapy. The combined modality treatment concept has to be considered for the therapy of advanced cervical cancer and a prospective and randomized trial with a greater number of patients is warranted.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">5-fluorouracil</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meerpohl, H.G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Henne, K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Du Bois, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Achterrath, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Frommhold, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pfleiderer, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International journal of gynecological cancer</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1991</subfield><subfield code="g">6(1996), 1, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926197</subfield><subfield code="w">(DE-600)2009072-9</subfield><subfield code="x">1525-1438</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:1996</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1525-1438.1996.06010020.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">1996</subfield><subfield code="e">1</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3997803 |